The use of Eliquis (apixaban) on the NHS has been recommended by NICE as a treatment option for the prevention of venous thromboembolism (VTE) for those who have had a total hip or knee replacement.
Professor Carole Longson, NICE Health Technology Evaluation Centre Director, says t hat Eliquis “is a clinically and cost effective option”.
Patients undergoing hip and knee replacement surgery have a high risk of developing VTE – a term to describe the conditions of deep vein thrombosis and pulmonary embolism.
Last year more than 120,000 hip and knee replacements were carried out in England and Wales. These procedures carry a high risk of VTE and require effective anticoagulation to protect patients from potentially fatal clots developing.
“We are pleased to have been able to produce final draft guidance on the use of apixaban just six months after it received its license for the prevention of VTE in patients who have undergone planned hip and knee surgery,” said Professor Longson.
Eliquis is manufactured by Pfizer and Bristol-Myers Squibb.